Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer
JCI Insight · 2025
DOI: 10.1172/jci.insight.187151 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Amanda B Hesterberg und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine. Hauptthemen laut MEDLINE: Receptor, ErbB-3, Prostatic Neoplasms, Saporins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, American Cancer Society.
Abstract (Originalsprache)
Cancer-associated fibroblasts (CAFs) are part of the tumor microenvironment (TME) that enable cancer cells to establish metastases, but the mechanisms of these interactions are not fully known. Herein, we identified a paracrine mechanism in which CAF-secreted asporin (ASPN) activated ErbB signaling and subsequent migration of adjacent prostate cancer cells. Our data support that ASPN bound directly to the ligand binding domain of human epidermal growth factor 3 (HER3) and induced HER2/HER3 heterodimerization and activation of the PI3K, MAPK, and calcium pathways. Genetic and therapeutic inhibition of HER2/HER3 ablated ASPN-induced signaling and migration. Clinically, ASPN was detected in the stroma of HER2/HER3-expressing human metastatic prostate cancer, supporting the clinical relevance of these findings and highlighting a potential therapeutic vulnerability. Antibody-drug conjugate (ADC) therapies designed to target HER2 (trastuzumab-deruxtecan) or HER3 (patritumab-deruxtecan) significantly diminished prostate cancer cell growth in vitro and tumor size in vivo, despite Aspn in the TME. Collectively, these findings indicate ASPN functions as a HER3 ligand to induce cellular migration, and inhibition with anti-HER2 or anti-HER3 ADC therapies highlights potential clinical utility for patients with metastatic castration-resistant prostate cancer that expresses HER2 or HER3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine.
- Department of Pathology, Microbiology and Immunology, and.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Chemistry.
- Vanderbilt Institute of Chemical Biology, and.
- Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA.
Förderung
- NCI NIH HHS
- NIH HHS
- American Cancer Society
- National Cancer Institute
- National Cancer Center
Zitieren
APA
Hesterberg, A. B., Wong, H. Y., Jackson, J., Antunovic, M., Rios, B. L., Watkins, E., Bergman, R. E., Davidson, B. A., Ginther, S. E., Graves, D., Nahmias, E. F., Googel, J. A., Martin, L. B., Sanchez, V., Gonzalez-Ericsson, P. I., Sheng, Q., Brown, B. P., Meiler, J., Schaffer, K. R., …, & Hurley, P. J. (2025). Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer. JCI Insight. https://doi.org/10.1172/jci.insight.187151
Vancouver
Hesterberg AB, Wong HY, Jackson J, Antunovic M, Rios BL, Watkins E, et al. Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer. JCI Insight. 2025. doi:10.1172/jci.insight.187151
BibTeX
@article{Hesterberg2025,
author = {Hesterberg, Amanda B and Wong, Hong Yuen and Jackson, Jorgen and Antunovic, Monika and Rios, Brenda L and Watkins, Evan and Bergman, Riley E and Davidson, Brad A and Ginther, Sarah E and Graves, Diana and Nahmias, Elliott F and Googel, Jared A and Martin, Lillian B and Sanchez, Violeta and Gonzalez-Ericsson, Paula I and Sheng, Quanhu and Brown, Benjamin P and Meiler, Jens and Schaffer, Kerry R and Gordetsky, Jennifer B and Park, Ben H and Hurley, Paula J},
title = {Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer},
journal = {JCI Insight},
year = {2025},
doi = {10.1172/jci.insight.187151}
}
EUVIMED